Medical Oncology, Dana-Farber Cancer Center, Boston, MA, USA.
Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Nat Commun. 2022 Jun 15;13(1):3449. doi: 10.1038/s41467-022-30694-w.
Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with significant heterogeneity in disease progression. Existing clinical models of progression risk do not fully capture this heterogeneity. Here we integrate 42 genetic alterations from 214 SMM patients using unsupervised binary matrix factorization (BMF) clustering and identify six distinct genetic subtypes. These subtypes are differentially associated with established MM-related RNA signatures, oncogenic and immune transcriptional profiles, and evolving clinical biomarkers. Three genetic subtypes are associated with increased risk of progression to active MM in both the primary and validation cohorts, indicating they can be used to better predict high and low-risk patients within the currently used clinical risk stratification models.
冒烟型多发性骨髓瘤(SMM)是多发性骨髓瘤(MM)的前体状态,疾病进展存在显著异质性。现有的临床进展风险模型不能完全捕捉到这种异质性。在这里,我们使用无监督二进制矩阵分解(BMF)聚类整合了 214 例 SMM 患者的 42 种基因改变,并鉴定出六个不同的基因亚型。这些亚型与已确立的 MM 相关 RNA 特征、致癌和免疫转录谱以及不断发展的临床生物标志物存在差异相关。在原发性和验证队列中,有三个基因亚型与进展为活动性 MM 的风险增加相关,这表明它们可用于更好地预测当前使用的临床风险分层模型中高危和低危患者。